> Bekis > Projects > View project

Projects

Implications of Biomedicine for the Assessment of Human Health Risks (IMBA) - [German]


Duration:

Jul 2006 - Mar 2009

Contact:

Tannert, Christof (Dr.)

Research Group Bioethics and Science Communication

Max Delbrueck Center for Molecular Medicine

Robert-Rössler-Str. 10

13125 Berlin

Germany

Phone: +49-(0)309406-2203

E-Mail: tannert@mdc-berlin.de
URL: http://www.bioethik-diskurs.de/documents/Aktu...ml/view

Head:

Dr. Peter Wiedemann

Research Center Jülich

Programme Group M.U.T.

Member:

Dr. Christof Tannert

Max Delbrueck Center for Molecular Medicine (MDC)

Berlin-Buch

Short Description:

IMBA is a health technology assessment (TA) project. It will analyse how specific new developments in biomedicine, which are often summarized under the term “toxicogenomics”, will transform the present risk management framework. The focus of our research will be on the impacts - both challenges and opportunities - on risk characterization, risk perception, and risk communication. IMBA is an international project of the Strategy Group "Systems Analysis and Technology Assessment in the Helmholtz Association (HGF)”.

Keywords

technology assessment

© DRZE, 2005-2012 | Imprint | webmaster@drze.de